Ribo files EU trial application for dual-target lipid siRNA SR122

Suzhou Ribo Life Science and Ribocure filed an EU Phase 1 CTA on Nov 10 for dual-target GalNAc siRNA SR122 (ApoC3/PCSK9), alongside Phase 2 RBD5044. Authorization and human data remain ahead.

Ribo files EU trial application for dual-target lipid siRNA SR122
Conceptual schematic of GalNAc-conjugated dual-target siRNA silencing across parallel lipid pathways (ApoC3 and PCSK9).

Suzhou Ribo Life Science and its Swedish subsidiary Ribocure Pharmaceuticals have submitted a European Union application for a Phase 1 study of SR122, an experimental siRNA therapy targeting both ApoC3 and PCSK9.

The company announced the submission on November 10. It describes SR122 as a GalNAc-conjugated therapy being developed for severe hypertriglyceridemia and mixed dyslipidemia. Submission is the disclosed regulatory milestone; the announcement does not report authorization or the start of dosing.

The proposed randomized, placebo-controlled study will evaluate subcutaneous SR122 in healthy participants, assessing safety, tolerability, pharmacokinetics and pharmacodynamics. It is intended to provide the first human assessment of the dual-target approach.

Ribo is also advancing RBD5044, its ApoC3-targeting siRNA, in Phase 2 studies in China and Europe. SR122 adds PCSK9 targeting to the company's lipid-development strategy, with the aim of addressing both triglyceride-rich lipoproteins and LDL cholesterol.

For readers tracking China's RNA drug developers, the distinction is between a broader biological proposition and evidence that it works in patients. The filing sets up an initial human test. It provides no clinical results demonstrating that SR122 improves lipid control, prevents cardiovascular events or offers an advantage over single-target therapies. Authorization, first dosing and the eventual safety and pharmacodynamic data are the next milestones to follow.

Related on China Pharma Desk: Hengrui’s China approval for ANGPTL3 lipid antibody SHR-1918 · AASLD 2026: GLP-1s vs. liver-directed siRNA in MASH